These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Development of therapeutic antibodies for the treatment of diseases. Lu RM; Hwang YC; Liu IJ; Lee CC; Tsai HZ; Li HJ; Wu HC J Biomed Sci; 2020 Jan; 27(1):1. PubMed ID: 31894001 [TBL] [Abstract][Full Text] [Related]
23. Recent developments in colorectal cancer treatment by monoclonal antibodies. Arsene D; Galais MP; Bouhier-Leporrier K; Reimund JM Expert Opin Biol Ther; 2006 Nov; 6(11):1175-92. PubMed ID: 17049015 [TBL] [Abstract][Full Text] [Related]
24. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies. Reinacher-Schick A; Pohl M; Schmiegel W Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435 [TBL] [Abstract][Full Text] [Related]
27. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032 [TBL] [Abstract][Full Text] [Related]
28. Current constructs and targets in clinical development for antibody-based cancer therapy. Deckert PM Curr Drug Targets; 2009 Feb; 10(2):158-75. PubMed ID: 19199912 [TBL] [Abstract][Full Text] [Related]
30. FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment. Wang B; Kokhaei P; Mellstedt H; Liljefors M Int J Oncol; 2010 Dec; 37(6):1599-606. PubMed ID: 21042730 [TBL] [Abstract][Full Text] [Related]
31. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330 [TBL] [Abstract][Full Text] [Related]
32. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
34. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Bodey B; Bodey B; Siegel SE; Kaiser HE Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic targets and new directions for antibodies developed for ovarian cancer. Bax HJ; Josephs DH; Pellizzari G; Spicer JF; Montes A; Karagiannis SN MAbs; 2016; 8(8):1437-1455. PubMed ID: 27494775 [TBL] [Abstract][Full Text] [Related]
36. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
37. Impact of OCT4 and Its Related Signaling Pathways on Gastrointestinal Cancers: Focusing on Targeted Therapy. Cheshomi H; Gholami O; Peyroshabani B; Rad A Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):229-242. PubMed ID: 32615657 [TBL] [Abstract][Full Text] [Related]
38. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Woodhouse CS; Morgan AC Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860 [TBL] [Abstract][Full Text] [Related]
39. Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy. Che Nordin MA; Teow SY Molecules; 2018 Feb; 23(2):. PubMed ID: 29415435 [TBL] [Abstract][Full Text] [Related]
40. [Target antigens for therapeutic antibodies in oncology: many candidates, few successes]. Ceze N; Probst A; Lecomte T; Ohresser M; Paintaud G; Watier H Bull Cancer; 2007; 94(7 Suppl):F129-36. PubMed ID: 17964990 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]